Page 9 - Nsclc News Today

Rates of early mortality from NSCLC decreased in states with Medicaid expansion, according to recent research.

A marketing authorization application seeking the approval of the combination of lazertinib and amivantamab in the first-line treatment of adult patients with advanced non­–small cell lung cancer harboring EGFR mutations has been submitted to the European Medicines Agency.

Edgardo Santos, MD, FACP, FCCP, analyzes the recent developments in the DESTINY-Lung01 and DESTINY-Lung02 trials, specifically focusing on HER2+ NSCLC patients with brain metastases and exploring the potential impact on clinical practice.

Giving a glimpse into significant data and highlighting the importance of balancing toxicities with efficacy as the non–small cell lung cancer treatment paradigm shifts.

Eduardo Santos, MD, FACP, FCCP, discusses recent advances in dual immunotherapy approaches for NSCLC, highlighting data from the CheckMate 9LA study.

A limited course of tremelimumab added to frontline durvalumab and chemotherapy provided a sustained overall survival benefit vs chemotherapy alone in patients with previously untreated metastatic non­–small cell lung cancer.

Lenvatinib plus pembrolizumab did not provide a survival advantage vs standard-of-care docetaxel in patients with advanced-stage non–small cell lung cancer who experienced disease progression following prior exposure to a PD-L1 inhibitor and platinum-based chemotherapy.

Discover the latest insights on treating uncommon EGFR mutations, emphasizing the importance of NGS, personalized therapy, and ongoing advancements in TKIs and ADCs.

The European Medicines Agency has validated its marketing authorization application for repotrectinib in adult patients with ROS1 TKI-naive or -pretreated locally advanced or metastatic non–small cell lung cancer harboring ROS1 fusions, as well as adult and pediatric patients with TKI-naive and pretreated NTRK-positive locally advanced or metastatic solid tumors.

A coformulation of vibostolimab and pembrolizumab with or without docetaxel failed to result in a statistically significant improvement in progression-free survival compared with docetaxel alone in patients with metastatic non­–small cell lung cancer.